Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-101 Phase 3 Open-label Study in Cytomegalovirus Corneal Endotheliitis
jRCT2051210064Phase 3Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ganciclovir, sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Virologic clearance in aqueous humor. Started Aug 2021; status: completed.
02
Drugs
ganciclovir
Beyond the preview
Go deeper on jRCT2051210064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210064.